You are here

Entasis

FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful

FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful

Endpoints

Intercept Pharma

sulbactam-durlobactam

obeticholic acid

Flag link:

Experimental treatment appears effective against gonorrhea in small study

Experimental treatment appears effective against gonorrhea in small study

Stat

Flag link:

Nasdaq triple IPO play brings in $345M as the big biotech party rocks on

Nasdaq triple IPO play brings in $345M as the big biotech party rocks on

Endpoints

Urovant Sciences

Sutro BioPharma

Flag link:

Entasis dips in first trading day after $75M IPO

Entasis dips in first trading day after $75M IPO

BioCentury

Flag link:

AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3

AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3

Fierce Biotech

clinical trials

Flag link:

Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis

Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis

Fierce Biotech

Flag link: